Clinical Study of IBI362 in Healthy Chinese Male Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 3, 2021

Primary Completion Date

March 9, 2021

Study Completion Date

June 17, 2021

Conditions

Overweight/Obesity

Interventions

DRUG

IBI362 liquid formulation

Administered by subcutaneous injection

DRUG

IBI362 lyophilized powder

Administered by subcutaneous injection

Trial Locations (1)

The Sceond Affiliated Hospital of Nanchang University, Nanchang

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT04773977 - Clinical Study of IBI362 in Healthy Chinese Male Subjects | Biotech Hunter | Biotech Hunter